ReCode Therapeutics公司今日宣布完成1.2亿美元B轮+轮融资，将B轮融资总值提高到2亿美元，由Sanofi Ventures、安进Amgen Ventures、Leaps by Bayer、辉瑞Pfizer投资。 免责声明：本内容来自腾讯平台创作者，不代表腾讯新闻或腾讯网的观点和立场。

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, ...

– Phase 1 trial to evaluate safety and tolerability of a single ascending dose of RCT1100, an inhaled mRNA-based genetic medicine – First clinical-stage candidate from ReCode’s proprietary SORT LNP ...